Literature DB >> 12084162

Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission.

David A Leiby1, Ross M Herron, Elizabeth J Read, Bruce A Lenes, Robert J Stumpf.   

Abstract

BACKGROUND: Trypanosoma cruzi, the agent of Chagas' disease, continues to be a concern for blood safety, as demonstrated by recent transfusion-transmitted cases in the United States and Canada. The chronic nature of Chagas', coupled with increasing numbers of immigrants from T. cruzi-endemic countries, suggests that Chagas' is a long-term public health problem. Herein, we report on a multiyear epidemiologic study of T. cruzi in Los Angeles and Miami blood donors. STUDY DESIGN AND METHODS: From May 1994 to September 1998, blood donors in Los Angeles and Miami were queried regarding birth or time spent in an endemic country. Donations of "yes" respondents were tested by EIA, confirmed by radioimmunoprecipitation assay, and if confirmed as seropositive, enrolled in look-back investigations.
RESULTS: A total of 1,104,030 Los Angeles and 181,139 Miami donors were queried regarding risk; 7.3 and 14.3 percent, respectively, responded yes. Seropositive rates were 1 in 7,500 Los Angeles and 1 in 9,000 Miami donors. In Los Angeles, seroprevalence rates increased significantly from 1996 to 1998 and were significantly higher for directed donors than nondirected donors. Look back identified 18 recipients, all of whom were seronegative for T. cruzi.
CONCLUSION: Significant numbers of T. cruzi-seropositive donors contribute to the U.S. blood supply. The incidence of seropositivity is enhanced by minority recruitment efforts necessitated by donor demographic shifts. Similarly, high rates among directed donations in Los Angeles are attributable to a disproportionate number of at-risk directed donors. Current look-back data likely underestimate the frequency of transfusion- transmitted T. cruzi. These results indicate that continued evaluation of transfusion as a mode of T. cruzi transmission in the United States is needed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084162     DOI: 10.1046/j.1537-2995.2002.00077.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  51 in total

1.  Development and comparison of enzyme immunoassays for diagnosis of Chagas' disease using fixed forms of Trypanosoma cruzi (Epimastigotes, Amastigotes, and Trypomastigotes) and assessment of antigen stability for the three assays.

Authors:  Mariolga Berrizbietia; Momar Ndao; Marcelo Gottschalk; Alberto Aché; Fabio Vásquez; Sonia Lacouture; Mehudy Medina; Brian J Ward
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

Review 2.  Adipocyte, adipose tissue, and infectious disease.

Authors:  Mahalia S Desruisseaux; Maria E Trujillo; Herbert B Tanowitz; Philipp E Scherer
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

3.  The Krever Commission--10 years later.

Authors:  Kumanan Wilson
Journal:  CMAJ       Date:  2007-11-20       Impact factor: 8.262

4.  The emergence of chagas disease in the United States and Canada.

Authors:  Louis V Kirchhoff; Richard D Pearson
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

Review 5.  Transmission of tropical and geographically restricted infections during solid-organ transplantation.

Authors:  P Martín-Dávila; J Fortún; R López-Vélez; F Norman; M Montes de Oca; P Zamarrón; M I González; A Moreno; T Pumarola; G Garrido; A Candela; S Moreno
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

6.  Trypanosoma cruzi in non-human primates with a history of stillbirths: a retrospective study (Papio hamadryas spp.) and case report (Macaca fascicularis).

Authors:  Jessica L Grieves; Gene B Hubbard; Jeff T Williams; John L Vandeberg; Edward J Dick; Juan C López-Alvarenga; Natalia E Schlabritz-Loutsevitch
Journal:  J Med Primatol       Date:  2008-07-30       Impact factor: 0.667

7.  Design of e-pharmacophore models using compound fragments for the trans-sialidase of Trypanosoma cruzi: screening for novel inhibitor scaffolds.

Authors:  Bill R Miller; Adrian E Roitberg
Journal:  J Mol Graph Model       Date:  2013-08-16       Impact factor: 2.518

8.  Polymerase chain reaction detection of Trypanosoma cruzi in Macaca fascicularis using archived tissues.

Authors:  Jeff T Williams; James N Mubiru; Natalia E Schlabritz-Loutsevitch; Rohina C Rubicz; John L VandeBerg; Edward J Dick; Gene B Hubbard
Journal:  Am J Trop Med Hyg       Date:  2009-08       Impact factor: 2.345

Review 9.  Current concepts in immunoregulation and pathology of human Chagas disease.

Authors:  Walderez O Dutra; Kenneth J Gollob
Journal:  Curr Opin Infect Dis       Date:  2008-06       Impact factor: 4.915

10.  Estimation of sensitivity and specificity of several Trypanosoma cruzi antibody assays in blood donors in Argentina.

Authors:  Mirta C Remesar; Cecilia Gamba; Ivana F Colaianni; Mónica Puppo; Paula A Sartor; Edward L Murphy; Torsten B Neilands; María A Ridolfi; M Susana Leguizamón; Silvina Kuperman; Ana E Del Pozo
Journal:  Transfusion       Date:  2009-11       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.